1. Home
  2. OGG vs IVA Comparison

OGG vs IVA Comparison

Compare OGG & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Osisko Gold Group Inc. Common Shares

OGG

Osisko Gold Group Inc. Common Shares

N/A

Current Price

$2.72

Market Cap

871.5M

Sector

N/A

ML Signal

N/A

Logo Inventiva S.A. American Depository Shares

IVA

Inventiva S.A. American Depository Shares

HOLD

Current Price

$3.76

Market Cap

895.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OGG
IVA
Founded
N/A
2011
Country
Canada
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
871.5M
895.3M
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
OGG
IVA
Price
$2.72
$3.76
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$16.20
AVG Volume (30 Days)
1.5M
1.1M
Earning Date
N/A
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$751.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.22
$3.35
52 Week High
$3.30
$7.98

Technical Indicators

Market Signals
Indicator
OGG
IVA
Relative Strength Index (RSI) 47.19 27.70
Support Level $2.69 $3.35
Resistance Level $2.89 $4.78
Average True Range (ATR) 0.12 0.27
MACD -0.04 -0.11
Stochastic Oscillator 30.39 2.78

Price Performance

Historical Comparison
OGG
IVA

About OGG Osisko Gold Group Inc. Common Shares

Osisko Gold Group Inc is a continental North American gold development company focused on past producing mining camps with district-scale potential. The company's objective is to become an intermediate gold producer through the development of its flagship, Cariboo Gold Project, located in central British Columbia, Canada. Its project portfolio also includes the Tintic Project in the East Tintic mining district of Utah, United States.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.

Share on Social Networks: